DTD4 Rec'd PCT/PTO 2 4 SEP 2001

		SHEET 1 OF
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. TOYA140.001APC	APPLICATION NO. Unknown 70 / 508980
INFORMATION DISCLOSURE STATEMENT		
BY APPLICANT	APPLICANT Kaji, et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE Herewith	GROUP Unknown
	U.S. PATENT DOCUMENTS	

		U.	S. PATENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING (IF APPRO	
		FOR	EIGN PATENT DOCUMENTS				
EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	

EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL							YES	NO
RX	+	WO 00/74703	12/14/00	WIPO				
	ſ	WO 97/35604	10/02/97	WIPO				
	1.	WO 96/11699	04/25/96	WIPO				
	\top							
	1							
	\top		- 					

EXAMINE F	R OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
4	,	Göschel, et al. *Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences,* Experimental Neurology, Vol. 147, pp. 98-102, 1997					

H:\DOCS\CSC\CSC-7803.DOC 092404

EXAMINER	Rosanne Kosson	DATE CONSIDERED 12/12/05	

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

: